Navigation Links
NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco

Management to Present at 9:45 a.m. on the 13th with Breakout Session to Follow

SANTA CLARA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Branislav Vajdic, the Company's Chief Executive Officer, and Vincent Renz, the Company's President, will present at the "OneMedForum 2009" finance conference, to be held January 13-14, 2009, in San Francisco at the Sir Francis Drake Hotel. NewCardio's presentation is scheduled for 9:45 a.m. on the 13th, with a 40-minute breakout session to follow. Management will be available for one-on-one meetings throughout the day.

The presentation will be webcast live and will be available at and also on the "News and Events" page at

In addition to the presentations by emerging medtech companies, there will be panels that will address the "drivers and disrupters" affecting each of the following medtech sectors: Orthopedics and Spine; Central Nervous System and Neurostimulation; Cardiology; Urology and Sexual Health; Advances in Surgery; Wound Care; Diagnostics; and, Healthcare Information Technology. These panels will include business development executives as well as venture capitalists who have invested in the eight sectors to be featured. They include: Brook Byers, Kleiner Perkins Caulfield & Byers; Alison de Bord, Alta Partners; David Douglass, Delphi Ventures; Richard Ferrari, De Novo Ventures; Peter Fitzgerald, MD, Latterell Ventures; Fred Middleton, Sanderling Ventures; Teo Forcht Dagi, MD, HLM Venture Partners; and, Jim Shapiro, Kearney Venture Partners. NewCardio will participate in the Cardiology panel.

About OneMedPlace

OneMedPlace is a virtual community of healthcare and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine -- emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link:

    Investor Contact:
    Hayden IR
    Jeff Stanlis, VP of Communications
    (602) 476-1821

SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure
2. NewCardio Announces New Client Services Team
3. Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008
4. Endocare to Present at 2nd Annual OneMedForum
5. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
6. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at JPMorgan Healthcare Conference
8. AMERIGROUP Corporation to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14
9. Gentiva(R) Health Services to Present January 13 at J.P. Morgan Healthcare Conference in San Francisco
10. IPC The Hospitalist Company, Inc. to Present at 27th Annual J.P. Morgan Healthcare Conference
11. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... announced that it has undertaken significant expansion of its current state of the ... is part of PharmaTech’s strategy to increase its manufacturing capacity as well as ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology: